New Brain and Whole Body Tissue Clearing|Register Now
»
Adverse Reactions Titles (Section 38 EMBASE)
 
 

Adverse Reactions Titles (Section 38 EMBASE)

Section 38

 
 

Journal

Show

00018848

50

12

Go to Journal Website

Print Journal

Subscription Details

Estimated Delivery Time


In Stock

USD 36,300.00
Terms & Conditions

Additional Subscription Help

 
 
 

Aims & Scope

Each year, approximately 400,000 articles appearing in over 4,000 biomedical and 200 chemical serials are scanned at Elsevier by medical specialists and pharmacologists. Each year, an average of 100,000 articles dealing with drugs and other biologically active substances are included in EMBASE, the Excerpta Medica database, of which an average of about 8,000 fall within the scope of Adverse Reactions Titles.

Since 1989 Elsevier has included abstracts with many of the citations published to increase the usefulness of this journal. Approximately 50% of published citations include abstracts.

Citations and abstracts (including those of original papers, preliminary communications, reviews, editorials and letters to the editor) are included if they contain significant information on:

• the complications, side effects and undesirable reactions produced by clinically used drugs;

• experimental and teratology to the extent that clinically used drugs are under investigation;

• suicide, attempted suicide, drug abuse and accidental over-dosage;

• detailed author and keyword indexes allow the reader to locate items of special interest.

Audience

Clinical pharmacologists in research, industry, drug regulatory agencies and practice; pharmacological toxicologists; general practitioners.

 
 
 
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us

Author Services

Prepare your Article for submission
Translation Services
English Language Editing
Illustrations

Celebrate your publication success
Article Offprints, Journal Issues, Article/Cover Posters, Create Your Own Book

Additional Services
Mobile Apps,Special Content Offerings,and more...